Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,852 questions in 128 reviews · Effective Practice and Organisation of Care
current versionsNo studies 557 · 30.1%Ungraded 53 · 2.9%Very low 446 · 24.1%Low 476 · 25.7%Moderate 255 · 13.8%High 65 · 3.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall use of medicines · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Use of medicines for symptomatic conditions · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for symptomatic conditions · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for asymptomatic conditions · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Cost · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Insurer perspective (expenditures on health care) · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcome · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Use of medicines for asymptomatic conditions · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall use of medicines · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for symptomatic conditions · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for asymptomatic conditions · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Cost · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Outpatient care · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Health outcomes · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall use of medicines · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for symptomatic conditions · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Use of medicines for asymptomatic conditions · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Cost · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Patient perspective · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Outpatient care · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | Low |
Intervention NR Health outcomes · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |